hPEBP4 Inhibited Rituximab-mediated Complement Dependent Cytotoxicity (R-CDC) and Antibody-dependent Cell-mediated Cytotoxicity (ADCC) in Human Lymphoma Cells. Here, PEBP4 is linked to lymphoma.